Biosimilar Comparability Studies

GMP-certified, EMA and FDA-inspected full biosimilar comparability studies following a step-by-step model.

Kymos Group is a GMP-certified an EMA and FDA inspected CRO offering full biosimilar comparability studies. Releasing biosimilar drugs to the market is extremely challenging. It calls for well-equipped laboratories able to conduct all assays, ensuring purity, identity and potency.

Labs providing biosimilar comparability studies need to have GMP certifications and manufacturing authorizations, subject to periodic inspections by regulatory bodies such as the FDA and the EMA. Kymos has all this. We follow a step-by-step comparability model for biosimilar drugs focused on critical quality attributes (CQAs), identified and classified according to their risk ranking.

Biopharmaceutical laboratoy

  • GENERAL ANALYTICAL TECHNIQUES FOR BIOSIMILARS

    A preliminary overview of the quality attributes of the biosimilar molecule during initial development phases:

    • Electrophoresis (PAGE, SDS-PAGE, Bioanalyzer, IEF)
    • Western Blot
    • Extinction Coefficient, Bradford, Lowry, BCA (total protein quantitation)
    • HPLC AccQ-Tag® (Waters) and OPA® (Agilent) for amino-acid analysis
    • Sulfide quantitation by Ellman method
    • Antibody isotyping

  • CONFORMATIONAL ANALYSIS OF THE BIOSIMILAR:

    Protein folding and 3D conformation determine biological activity and immunogenicity of the biosimilar:

    • Circular Dichroism (CD)
    • Ultraviolet spectroscopy (UV)
    • Fluorescence spectroscopy (FL)
    • Infrared spectroscopy (FTIR)

  • PROCESS-RELATED IMPURITIES:

    Other quality indicators of the purification process and also linked to safety concerns:

    • Host Cell Proteins (specific ELISA)
    • Chemical contaminants (HPLC, GC)
    • Elemental impurities (AAS, ICP-MS)
    • Nitrosamine impurities (LC-MS/MS, HS-GC-MS)
    • DNA (qPCR and colorimetric commercial kits)
    • Mycoplasma (PCR commercial kits)
    • Endotoxins (colorimetric, gel-clot test or turbidimetric)
    • Bioburden

  • STRUCTURAL ANALYSIS OF THE BIOSIMILAR:

    Full molecular identification of the biosimilar for strain selection, bioprocess and final product characterization:

    • Intact protein mass (Electrospray MS, MALDI-TOF)
    • Peptide mapping, amino acid sequencing (LC-UV-MS/MS, QTof, QTRAP)
    • N and C terminal sequencing of intact protein (MALDI-TOF and Edman degradation)
    • Glycosylation and phosphorylation sites (LC-UV-MS)
    • Glycosylation Profiles (GC, LC, MS/MS, capillary electrophoresis)
    • Monosaccharide profile (LC and GC)

  • IDENTITY, CONTENT, PROTEIN IMPURITIES:

    Chromatographic patterns are quality indicators of the purification process:

    • Liquid chromatographic patterns (RP-; SEC-; Ion Exchange-; and Affinity-HPLC/UPLC plus LC-UV-MS)
    • Electrophoresis (CE-SDS, SDS-PAGE, iclEF)
    • ELISA, Western Blot

  • BIOLOGICAL ACTIVITY OF THE BIOSIMILAR:

    Biological tests to confirm molecule activity of the biosimilar:

    • Binding studies (ELISA, Western Blot, SPR Biacore®)
    • Potency assays (Cell –based assays)
    • Competitive inhibition ELISA assays for vaccines

Services

Related services to Biosimilar Comparability Studies

Bioequivalence studies

Quality Control of Biologics and Biosimilars

Complex characterization projects for innovative biologics and comparison of biosimilars.

BSL2 testing room

Cell-Based and Potency Assays

We offer GLP Cell-based neutralizing antibody assays for biologics and GMP Cell-based potency assays for vaccines and other biologics.

Analytisches CRO HPLCs

Batch Testing and Batch Release

Our laboratories are GMP certified and we have a partial manufacturer authorization for Quality Control purposes.

Contact

Do you need more information or a quote?